Tempus AI and Recursion Pharmaceuticals have extended their data partnership through 2029, with Tempus committing to $42 million in payments over three years, replacing a potential $84 million. Tempus also gains a non-exclusive license to Recursion's RNA sequencing model, TxFM, which could enhance its precision medicine capabilities.
Tempus AI (TEM) and Recursion Pharmaceuticals (RXRX) have extended their data partnership through November 2029. This is significant because Tempus secures continued access to Recursion's data for its foundation models, crucial for its precision medicine initiatives. While the deal replaces potential $84 million in discretionary fees with $42 million in committed payments over three years, it provides Recursion with guaranteed revenue, albeit at a lower potential ceiling. Additionally, Tempus licensing Recursion's RNA sequencing model 'TxFM' could enhance its technological capabilities. For traders, TEM benefits from long-term data access and a new model, while RXRX gains revenue certainty but foregoes higher potential payments, making the immediate impact somewhat balanced for RXRX.